Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. It also has a collaboration agreement Lund University to develop stem cell-derived treatment for Parkinson's diseases; and Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone45-4444-8888
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$17.72 billion
Profitability
Miscellaneous
Employees43,202
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions
What is Novo Nordisk A/S's stock symbol?
Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."
How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?
Novo Nordisk A/S declared a special dividend on Thursday, August 9th. Investors of record on Monday, August 20th will be given a dividend of $0.4669 per share on Tuesday, August 28th. This represents a dividend yield of 1.72%. The ex-dividend date of this dividend is Friday, August 17th. View Novo Nordisk A/S's Dividend History.
How will Novo Nordisk A/S's stock buyback program work?
Novo Nordisk A/S declared that its Board of Directors has approved a share buyback plan on Friday, February 2nd 2018, which authorizes the company to repurchase shares, according to EventVestor. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Shares repurchase plans are generally an indication that the company's board believes its stock is undervalued.
How were Novo Nordisk A/S's earnings last quarter?
Novo Nordisk A/S (NYSE:NVO) posted its quarterly earnings data on Friday, May, 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.62 by $0.04. The business had revenue of $4.46 billion for the quarter, compared to analyst estimates of $4.35 billion. Novo Nordisk A/S had a return on equity of 78.28% and a net margin of 33.60%. View Novo Nordisk A/S's Earnings History.
When is Novo Nordisk A/S's next earnings date?
What price target have analysts set for NVO?
16 brokerages have issued 12 month target prices for Novo Nordisk A/S's shares. Their predictions range from $48.61 to $48.61. On average, they anticipate Novo Nordisk A/S's share price to reach $48.61 in the next year. This suggests a possible upside of 0.5% from the stock's current price. View Analyst Price Targets for Novo Nordisk A/S.
What is the consensus analysts' recommendation for Novo Nordisk A/S?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 2 sell ratings, 7 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novo Nordisk A/S.
Has Novo Nordisk A/S been receiving favorable news coverage?
Media headlines about NVO stock have trended neutral on Friday, InfoTrie reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Novo Nordisk A/S earned a news sentiment score of 0.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future.
Who are some of Novo Nordisk A/S's key competitors?
Some companies that are related to Novo Nordisk A/S include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), AbbVie (ABBV), Eli Lilly And Co (LLY), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Celgene (CELG), Bayer (BAYRY) and Shire (SHPG).
What other stocks do shareholders of Novo Nordisk A/S own?
Who are Novo Nordisk A/S's key executives?
Novo Nordisk A/S's management team includes the folowing people:
- Mr. Lars Fruergaard Jørgensen, Pres & CEO (Age 53)
- Dr. Mads Krogsgaard Thomsen, Exec. VP & Chief Science Officer (Age 59)
- Mr. Karsten Munk Knudsen, Exec. VP & CFO (Age 47)
- Mr. Lars Green, Exec. VP and Head of Bus. Services & Compliance (Age 52)
- Mr. Ole F. Ramsby, Sr. VP & Gen. Counsel of Legal Affairs
Who are Novo Nordisk A/S's major shareholders?
Novo Nordisk A/S's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.87%), Loomis Sayles & Co. L P (0.85%), BlackRock Inc. (0.35%), Folketrygdfondet (0.21%), Sustainable Growth Advisers LP (0.14%) and Everett Harris & Co. CA (0.13%). View Institutional Ownership Trends for Novo Nordisk A/S.
Which institutional investors are selling Novo Nordisk A/S stock?
NVO stock was sold by a variety of institutional investors in the last quarter, including Alta Capital Management LLC, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA, Folketrygdfondet, JPMorgan Chase & Co., Hutchinson Capital Management CA, Jane Street Group LLC, Comerica Bank and Goldman Sachs Group Inc.. View Insider Buying and Selling for Novo Nordisk A/S.
Which institutional investors are buying Novo Nordisk A/S stock?
NVO stock was acquired by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Jennison Associates LLC, Renaissance Technologies LLC, Raymond James & Associates, Bain Capital Public Equity Management LLC, Connor Clark & Lunn Investment Management Ltd., Richard C. Young & CO. LTD. and SEI Investments Co. View Insider Buying and Selling for Novo Nordisk A/S.
How do I buy shares of Novo Nordisk A/S?
Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novo Nordisk A/S's stock price today?
One share of NVO stock can currently be purchased for approximately $48.38.
How big of a company is Novo Nordisk A/S?
Novo Nordisk A/S has a market capitalization of $118.22 billion and generates $17.72 billion in revenue each year. The company earns $5.91 billion in net income (profit) each year or $2.52 on an earnings per share basis. Novo Nordisk A/S employs 43,202 workers across the globe.
What is Novo Nordisk A/S's official website?
How can I contact Novo Nordisk A/S?
Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]
MarketBeat Community Rating for Novo Nordisk A/S (NYSE NVO)
MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote "Outperform" if you believe NVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
